Application of new guidelines for the primary prevention of atherosclerotic cardiovascular disease in a Korean population

Journal of Atherosclerosis and Thrombosis

Volumn 22, Issue 3, 2015, Pages 293-303

  Kim, Nan Hee ^a   So, Min Suk ^b   Kang, Jeong Gyu ^b   Cho, Dong Sik ^c   Byrne, Christopher D ^d   Lee, Sang Jong ^a   Sung, Ki Chul ^b  

^a CHA University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Guro Teun Teun Hospital   (South Korea)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Coronary artery calcium; Guidelines; Risk factor; Statin

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD ANALYSIS; BODY MASS; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY CALCIUM SCORE; DIABETES MELLITUS; DISEASE ASSOCIATION; ECHOGRAPHY; FATTY LIVER; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRACTICE GUIDELINE; QUESTIONNAIRE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; MIDDLE AGED; PRIMARY PREVENTION; SOUTH KOREA;

ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; GUIDELINES AS TOPIC; HUMANS; MIDDLE AGED; PRIMARY PREVENTION; REPUBLIC OF KOREA;

EID: 84925348599     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.26682     Document Type: Article

References (30)

1. Expert Panel on Detection, Evaluation: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486- 2497
2. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, for the Coordinating Committee of the National Cholesterol Education Program Endorsed by the National Heart, Lung, Blood Institute, American College of Cardiology Foundation, American Heart Association: Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 2004; 110: 227-239
3. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VLM, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK: From Vulnerable Plaque to Vulnerable Patient-Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report. Am J Cardiol, 2006; 98: 2-15
4. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013
5. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte Jr M, Detrano R: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol, 1990; 15: 827-832
6. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 2002; 123: 745-750
7. Bhatia LS, Curzen NP, Calder PC, Byrne CD: Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor ? Eur Heart J, 2012; 33: 1190-1200
8. Minder CM, Blumenthal RS, Blaha MJ: Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol, 2013; 28: 554- 560
9. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, de Craen AJM, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ, 2009; 338: b2376
10. Cholesterol Treatment Trialists C: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012; 380: 581-590
11. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. Circulation, 2008; 117: 743-753
12. Forman DE, Rich MW, Alexander KP, Zieman S, Maurer MS, Najjar SS, Cleveland Jr JC, Krumholz HM, Wenger NK: Cardiac Care for Older Adults: Time for a New Paradigm. J Am Coll Cardiol, 2011; 57: 1801-1810
13. Fried TR, Tinetti ME, Towle V, O'Leary JR, Iannone L: Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med, 2011; 171: 923-928
14. Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R: Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly? Stroke, 2007; 38: 441-450
15. LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Newman AB, Kooperberg CL, Black H, Curb JD, Greenland P, Woods NF: Statin Use and Incident Frailty in Women Aged 65 Years or Older: Prospective Findings From the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci, 2008; 63: 369-375
16. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S: Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. Circulation, 2007; 115: 27-33
17. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM: Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials. Circulation, 2006; 114: 2788-2797
18. McKenney JM, Davidson MH, Jacobson TA, Guyton JR: Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol, 2006; 97: S89-S94
19. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, Members WC: ACC/AHA/ NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation, 2002; 106: 1024-1028
20. Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T: Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk: Analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation, 2012; 126: 934- 941
21. Bukkapatnam RN, Gabler NB, Lewis WR: Statins for Primary Prevention of Cardiovascular Mortality in Women: A Systematic Review and Meta-Analysis. Prev Cardiol, 2010; 13: 84-90
22. Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, Uchiyama S, Nakamura H, for the MEGA Study Group: Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study). Circulation, 2008; 117: 494-502
23. Yoon YE, Rivera JJ, Kwon DA, Chae IH, Jeong MH, Rha SW, Blumenthal RS, Nasir K, Chang HJ; other Korea Acute Myocardial Infarction Registry Investigators. National Cholesterol Education Panel III Guidelines Performance Role in Preventing Myocardial Infarction in a Large Cohort Without a History of Coronary Artery Disease: Korea Acute Myocardial Infarction Registry Study. Prev Cardiol, 2009; 12: 109-113
24. Choi SJ, Park SH, Lee KS, Park HY. The Prevalence, Awareness and Treatment of High Low Density Lipoprotein- Cholesterol in Korean Adults Without Coronary Heart Diseases. Korean Circ J, 2012; 42: 86-94
25. Miyauchi K, Daida H. Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease. LDL-Cholesterol: The Lower, the Better; Is It True for Asians ? (Pro). Circ J, 2010; 74: 1718-1730
26. Sakamoto T, Ogawa H. "Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients. LDL-Cholesterol: The Lower, the Better; Is It True for Asians ? (Con). Circ J, 2010; 74: 1731-1741
27. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society (JAS). Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012. J Atheroscler Thromb, 2013; 20: 603-615
28. Arai H, Sasaki J, Teramoto T: Comment on the new guidelines in USA by the JAS guidelines committee. J Atheroscler Thromb, 2014; 21: 79-81
29. Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, Kelemen L, Yi C, Lonn E, Gerstein H, Hegele RA, McQueen M: Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet, 2000; 356: 279- 284
30. Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S: Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. Can Med Assoc J, 1999; 161: 132-138